Mission statement · Company scope
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”
In use2023 – now1 sighting
First seenJul 2023Added
Last seenJul 2023Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Innovation (primary) · Problem–solution
- Leads with
- Invention
- Best for
- Climate & health
- Formula
- We’re building [new thing] so [result]
- Tone
- Technical
- Length
- 31 words · reading grade 20.9
- Review status
- auto accepted · classifier rules-v0
- Quality score
- 0.76
- Record
- st_d7d2587d12cde763
- Classification confidence
- 0.87
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2023-07-31 · sec_sentence · 20-F · accession 0001171843-23-004814
View filing ↗0 to compareCompare